Weekly Investment Analysts’ Ratings Updates for CME Group (CME)

Several brokerages have updated their recommendations and price targets on shares of CME Group (NASDAQ: CME) in the last few weeks:

• 7/23/2026 – CME Group had its price target raised by Morgan Stanley from $324.00 to $330.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – CME Group had its price target raised by Bank of America Corporation from $226.00 to $230.00. They now have an “underperform” rating on the stock.
• 7/23/2026 – CME Group had its price target raised by JPMorgan Chase & Co. from $249.00 to $250.00. They now have an “underweight” rating on the stock.
• 7/15/2026 – CME Group had its price target lowered by Piper Sandler from $329.00 to $295.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – CME Group was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 7/12/2026 – CME Group was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/10/2026 – CME Group had its price target lowered by Morgan Stanley from $353.00 to $324.00. They now have an “overweight” rating on the stock.
• 7/9/2026 – CME Group had its price target lowered by Barclays PLC from $316.00 to $270.00. They now have an “equal weight” rating on the stock.
• 7/6/2026 – CME Group had its price target lowered by UBS Group AG from $310.00 to $260.00. They now have a “buy” rating on the stock.
• 7/6/2026 – CME Group had its price target lowered by UBS Group AG from $310.00 to $260.00. They now have a “neutral” rating on the stock.
• 7/2/2026 – CME Group had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $320.00 price target on the stock.
• 6/30/2026 – CME Group had its price target lowered by The Goldman Sachs Group, Inc. from $267.00 to $245.00. They now have a “sell” rating on the stock.
• 6/25/2026 – CME Group was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 6/22/2026 – CME Group had its price target lowered by TD Cowen from $323.00 to $273.00. They now have a “buy” rating on the stock.
• 6/18/2026 – CME Group was upgraded by Keefe, Bruyette & Woods from “market perform” to “outperform”. They now have a $305.00 price target on the stock.
• 6/17/2026 – CME Group was given a new $320.00 price target by Piper Sandler.
• 6/15/2026 – CME Group had its “overweight” rating reaffirmed by Piper Sandler. They now have a $329.00 price target on the stock.
• 6/15/2026 – CME Group had its “overweight” rating reaffirmed by UBS Group AG.
• 6/13/2026 – CME Group was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/11/2026 – CME Group was downgraded by Weiss Ratings from “buy (a-)” to “buy (b+)”.
• 6/11/2026 – CME Group was upgraded by Rothschild & Co Redburn from “neutral” to “buy”. They now have a $323.00 price target on the stock, up from $316.00.
• 6/5/2026 – CME Group was downgraded by Erste Group Bank AG from “buy” to “hold”.
• 5/29/2026 – CME Group had its “buy (a-)” rating reaffirmed by Weiss Ratings.

CME Group Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Tuesday, June 9th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.0%. CME Group’s payout ratio is presently 44.11%.

Insider Activity at CME Group

In other CME Group news, Director William R. Shepard purchased 325 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was acquired at an average price of $230.57 per share, with a total value of $74,935.25. Following the acquisition, the director directly owned 260,442 shares of the company’s stock, valued at $60,050,111.94. This trade represents a 0.12% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Terrence A. Duffy sold 35,000 shares of CME Group stock in a transaction on Friday, May 15th. The stock was sold at an average price of $298.51, for a total transaction of $10,447,850.00. Following the transaction, the chief executive officer directly owned 55,630 shares of the company’s stock, valued at approximately $16,606,111.30. This trade represents a 38.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.30% of the stock is owned by company insiders.

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.